2025-04-14 マウントサイナイ医療システム (MSHS)
<関連情報>
- https://www.mountsinai.org/about/newsroom/2025/mount-sinai-dermatologists-show-promising-results-using-combination-therapy-for-vitiligo-patients
- https://www.jaad.org/article/S0190-9622(24)03381-4/fulltext
活動性非分節性白斑患者におけるリトレシチニブと狭帯域紫外線Bの併用療法または非併用療法に対する反応性: 第2b相延長試験の結果 Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study
Yuji Yamaguchi, MD, PhD ∙ Elena Peeva, MD ∙ Roni Adiri, MSc, PhD ∙ … ∙ Ronald N. Shore, MD ∙ Khaled Ezzedine, MD, PhD ∙ Emma Guttman-Yassky, MD, PhD
Journal of the American Academy of Dermatology Published:December 18, 2024
DOI:https://doi.org/10.1016/j.jaad.2024.11.064
Abstract
Background
Ritlecitinib demonstrated efficacy in a phase 2b trial of nonsegmental vitiligo.
Objective
To evaluate the efficacy and tolerability of ritlecitinib with add-on narrow-band ultraviolet B (nbUVB) phototherapy in patients with nonsegmental vitiligo.
Methods
Following a 24-week, placebo-controlled, dose-ranging period, patients received ritlecitinib 200 mg for 4 weeks then 50 mg for 20 weeks, with or without nbUVB phototherapy 2x/week. Missing data were handled using last observation carried forward and observed case (OC).
Results
Forty-three patients received ritlecitinib + nbUVB and 187 received ritlecitinib-monotherapy. Nine patients receiving ritlecitinib + nbUVB discontinued due to nbUVB group-specific efficacy criteria requiring >10% improvement in % change from baseline (% change from baseline) in Total-Vitiligo Area Scoring Index at week 12. At week 24, mean % change from baseline in Facial-VASI score was -57.0 vs -51.5 (last observation carried forward; P = .158) and -69.6 vs -55.1 (OC; P = .009), for ritlecitinib + nbUVB vs ritlecitinib-monotherapy, respectively. Mean % change from baseline in Total-Vitiligo Area Scoring Index at week 24 was -29.4 vs -21.2 (last observation carried forward; P = .043) and -46.8 vs -24.5 (OC; P < .001), respectively. nbUVB addition to ritlecitinib was well tolerated with no new safety signals.
Limitations
Exploratory analysis; discontinuation criterion applied only to the ritlecitinib + nbUVB group; small sample size.
Conclusion
Ritlecitinib alone and with nbUVB therapy improved facial and total body repigmentation and was well tolerated. Adding nbUVB may improve ritlecitinib efficacy.
